See more : The Sukhjit Starch & Chemicals Limited (SUKHJITS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of IntelGenx Technologies Corp. (IGXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IntelGenx Technologies Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ZTEST Electronics Inc. (ZTE.CN) Income Statement Analysis – Financial Results
- Wielton S.A. (WLT.WA) Income Statement Analysis – Financial Results
- Telefonaktiebolaget LM Ericsson (publ) (ERIXF) Income Statement Analysis – Financial Results
- Red Lake Gold Inc. (RGLD.CN) Income Statement Analysis – Financial Results
- NAVKAR URBANSTRUCTURE LIMITED (NAVKAR.BO) Income Statement Analysis – Financial Results
IntelGenx Technologies Corp. (IGXT)
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 950.00K | 1.54M | 1.54M | 742.00K | 1.82M | 5.20M | 5.22M | 5.10M | 1.66M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 1.86M | 2.26M | 1.48M | 0.00 | 0.00 | 373.00K | 319.00K | 433.00K | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -694.00K | -908.00K | -721.00K | 67.00K | 742.00K | 1.82M | 4.82M | 4.90M | 4.66M | 1.60M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -66.79% | -95.58% | -46.97% | 4.34% | 100.00% | 100.00% | 92.82% | 93.89% | 91.50% | 96.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.43M | 3.03M | 2.72M | 2.64M | 3.77M | 5.10M | 2.62M | 1.77M | 1.03M | 1.08M | 561.00K | 1.72M | 1.34M | 1.57M | 1.42M | 2.09M | 603.40K | 510.41K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.76M | 4.70M | 3.75M | 4.44M | 5.80M | 5.00M | 3.97M | 3.61M | 2.07M | 2.29M | 1.95M | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 919.62K | 488.60K | 9.91K | 7.55K | 108.00 |
| Other Expenses | 0.00 | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | -237.90K | -376.84K | -132.37K | 33.91K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.51M | 7.26M | 7.81M | 10.29M | 10.82M | 7.32M | 5.88M | 3.28M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Cost & Expenses | 10.68M | 10.36M | 9.52M | 7.81M | 10.29M | 10.82M | 7.69M | 6.20M | 3.71M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Interest Income | 41.00K | 4.00K | 152.00K | 422.00K | 97.00K | 11.00K | 11.00K | 4.00K | 28.00K | 34.00K | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 30.86K | 27.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.28M | 1.49M | 1.20M | 1.21M | 1.12M | 569.00K | 203.00K | 123.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | 784.40K | 766.14K | 349.11K | 54.72K | 1.22K | 297.00 | 0.00 |
| Depreciation & Amortization | 766.00K | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | 44.60K | 51.77K | 42.01K | 33.91K | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.69M | -8.64M | -7.04M | -5.11M | -8.74M | -8.28M | -1.76M | -470.00K | 1.59M | -1.71M | -1.57M | -2.22M | -2.60M | -3.14M | -1.24M | -2.45M | -948.17K | -731.53K | -146.53K | -7.55K | -108.00 |
| EBITDA Ratio | -739.65% | -908.63% | -458.57% | -330.83% | -1,177.22% | -453.29% | -33.63% | -8.93% | 31.11% | -102.83% | -165.30% | -178.81% | -547.50% | -221.24% | -97.11% | -219.13% | -68.71% | -290.98% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.49M | -9.41M | -7.98M | -6.26M | -9.55M | -9.00M | -2.49M | -981.00K | 1.39M | -1.78M | -1.64M | -2.21M | -2.45M | -3.00M | -1.29M | -2.19M | -729.62K | -767.02K | -9.91K | -7.55K | -108.00 |
| Operating Income Ratio | -913.47% | -990.84% | -520.00% | -405.70% | -1,287.06% | -493.31% | -47.99% | -18.79% | 27.20% | -107.29% | -172.89% | -182.62% | -555.91% | -224.53% | -100.60% | -224.43% | -87.34% | -288.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -436.00K | -1.28M | -1.34M | -780.00K | -1.11M | -1.11M | -558.00K | -199.00K | -95.00K | 34.00K | 0.00 | 10.00K | 172.00K | -558.00K | -686.70K | -306.67K | -196.81K | -14.12K | 35.29K | 0.00 | 0.00 |
| Income Before Tax | -9.93M | -10.69M | -9.32M | -7.04M | -10.66M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -2.07M | -2.96M | -1.16M | -781.14K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -955.44% | -1,125.26% | -607.04% | -456.22% | -1,436.66% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -161.94% | -302.88% | -139.44% | -293.77% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.28M | -6.00K | 1.20M | 1.21M | 11.00K | 11.00K | 4.00K | 28.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | -130.30K | -151.58K | -64.08K | 14.12K | 11.12K | 7.84K | 108.00 |
| Net Income | -9.93M | -11.97M | -9.31M | -8.25M | -11.87M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -1.94M | -2.81M | -1.10M | -781.14K | -11.12K | -7.84K | -108.00 |
| Net Income Ratio | -955.44% | -1,259.68% | -606.64% | -534.07% | -1,599.33% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -151.75% | -287.36% | -131.77% | -293.77% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 63.52M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 70.86M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor
SAINT LAURENT, Quebec, Nov. 10, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that its third quarter 2022 conference call, originally scheduled for today, will now be held tomorrow (Friday, November...
IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 03, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2022 financial results after market close on Thursday, November 10, 2022.
IntelGenx Technologies Corp's (IGXT) CEO Horst Zerbe on Q2 2022 Results - Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Horst Zerbe – Chief Executive Officer André Godin – President and Chief Financail Officer Dana Matzen – Vice...
IntelGenx Technologies' (IGXT) CEO Horst Zerbe on Q1 2022 Results - Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Horst Zerbe – Chief Executive Officer André Godin – President and Chief Financial Officer Dana Matzen – Vice President-Business and Corporate Development Tommy...
IntelGenx to Report First Quarter 2022 Financial Results on May 12, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, May 05, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2022 financial results after market close on Thursday, May 12, 2022.
IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
SAINT LAURENT, Quebec, April 26, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that management will present an update on the Company's business at the Bloom Burton & Co. Healthcare Investor...
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q4 2021 Results - Earnings Call Transcript
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q4 2021 Results - Earnings Call Transcript
IntelGenx to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 – Conference Call to Follow
SAINT LAURENT, Quebec, March 17, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2021 financial results after market close on Thursday,...
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2021 Results - Earnings Call Transcript
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2021 Results - Earnings Call Transcript
IntelGenx to Report Third Quarter 2021 Financial Results on November 11, 2021 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2021 financial results after market close on Thursday, November 11, 2021.
Source: https://incomestatements.info
Category: Stock Reports